An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Odevixibat (Primary)
- Indications Intrahepatic cholestasis
- Focus Therapeutic Use
- Acronyms PEDFIC 2
- Sponsors Albireo AB; Albireo Pharma
- 18 Nov 2024 According to Ipsen media release, efficacy and safety data from this study will be presented at the American Association for the Study of Liver Diseases (AASLD).
- 18 Nov 2024 Results presented in the Ipsen Media Release.
- 26 Jul 2024 This trial has been completed in Poland, according to European Clinical Trials Database.